Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways
Oncology Reports · 2023
DOI: 10.3892/or.2023.8480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2023. Verfasst von Jong Seung Lim und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 16419, Republic of Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Histone Deacetylase Inhibitors, Antineoplastic Agents, Saxifragaceae. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 16419, Republic of Korea.
Zitieren
APA
Lim, J. S., Kyung, S. Y., Jeon, Y., Kim, I. S., Kwak, J. H., & Kim, H. S. (2023). Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways. Oncology Reports. https://doi.org/10.3892/or.2023.8480
Vancouver
Lim JS, Kyung SY, Jeon Y, Kim IS, Kwak JH, Kim HS. Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways. Oncology Reports. 2023. doi:10.3892/or.2023.8480
BibTeX
@article{Lim2023,
author = {Lim, Jong Seung and Kyung, So Young and Jeon, Yukyoung and Kim, In Su and Kwak, Jong Hwan and Kim, Hyung Sik},
title = {Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways},
journal = {Oncology Reports},
year = {2023},
doi = {10.3892/or.2023.8480}
}
EUVIMED